This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
A final decision on the updated application is expected in the first half of 2026, while intravenous (IV) Saphnelo remains commercially available
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Subscribe To Our Newsletter & Stay Updated
